Neurodevelopmental Disorders
These are a group of conditions with onset in the developmental period. The disorders typically manifest early in development, often before the child enters grade school, and are characterized by developmental deficits that produce impairments of personal, social, academic, or occupational functioning. (From DSM-5).
Subtype terms (14)
More specific conditions that are subtypes of Neurodevelopmental Disorders in the MeSH hierarchy.
- Anxiety, Separation
11 drugs approved
- Attention Deficit and Disruptive Behavior Disorders
72 drugs (42 approved, 30 experimental)
- Child Behavior Disorders
2 drugs approved
- Child Development Disorders, Pervasive
14 drugs (12 approved, 2 experimental)
- Communication Disorders
2 drugs (1 approved, 1 experimental)
- Developmental Disabilities
12 drugs (10 approved, 2 experimental)
- Intellectual Disability
41 drugs (33 approved, 8 experimental)
- Learning Disabilities
8 drugs (6 approved, 2 experimental)
- Motor Skills Disorders
1 drug approved
- Mutism
2 drugs approved
- Reactive Attachment Disorder
- Schizophrenia, Childhood
2 drugs approved
- Stereotypic Movement Disorder
- Tic Disorders
14 drugs (8 approved, 6 experimental)
Drugs by status
Phase 4 trials (5)
Phase 3 trials (7)
Phase 2 trials (12)
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (3)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (4)